Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse.
New Zealand Black/New Zealand White (NZB/W) mice, a model of systemic lupus erythematosus (SLE), have age-dependent loss of interleukin-2 (IL-2) production. To determine if replacement therapy would influence the course of autoimmune disease, we injected groups of NZB/W mice with low-dose (1,500 units/day) or high-dose (15,000 units/day) purified human recombinant IL-2. Parameters of active SLE and populations of splenocytes were not altered consistently by long-term treatment with either dose of IL-2.
Owen
K L
KL
Department of Laboratory Animal Medicine, University of Missouri, Columbia.
Shibata
T
T
Izui
S
S
Walker
S E
SE
D000818:Animals; D001323:Autoantibodies; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D006023:Glycoproteins / Q000097:blood; D006403:Hematologic Tests; D007136:Immunoglobulins / Q000032:analysis; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D051379:Mice; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use
D001323:Autoantibodies; D006023:Glycoproteins; D007136:Immunoglobulins; D007376:Interleukin-2; D011994:Recombinant Proteins; C033589:glycoprotein gp70, murine serum